Ann: Canaccord to Lead LSE Listing and $4.75m Placement Closed, page-111

From the email....

MGC Pharmaceuticals Limited (‘MXC’: Your Report of Misconduct

ASX refers to your online report of 7 August 2019 raising concerns about MGC’s disclosure with respect to the value of the sale of MGC Derma to CannaGlobal.
ASX would like to thank you for making the time and effort to bring these matters to its attention. These types of communications are an important source of intelligence for ASX in performing its role of monitoring and enforcing compliance with the ASX Listing Rules.
ASX refers to our letter to you dated 5 March 2019 with reference xxxxxxxx in relation to this matter (the “Letter”. As stated in the Letter, you will need to review MXC’s next accounts for the period ended 30 June 2019 for the value of the 10% equity interest in CannaGlobal. ASX notes that preliminary final reports are due to be released to the ASX Market Announcement Platform by MXC by no later than 30 August 2019 with final audited accounts due to be released by no later than 30 September 2019 for the period ending 30 June 2019.
For any further questions in relation to this matter, please direct your enquiries to MXC.
We hope this letter has helped clarify the situation.
Regards